FRI0397 Baseline characteristics of systemic sclerosis patients with borderline mean pulmonary artery pressure: post-hoc analysis from the detect study

Autor: Vallerie V. McLaughlin, Oliver Distler, Christopher P. Denton, Dinesh Khanna, Ulf Müller-Ladner, JG Coghlan, Madelon C. Vonk, Diana Bonderman, Martin Doelberg, Janet E. Pope, J.-V. Torres-Martin, Harald Heinzl, Ekkehard Grünig, Daniel M Rosenberg, Harbajan Chadha-Boreham, James R. Seibold
Rok vydání: 2013
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 72:A507.2-A508
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2013-eular.1524
Popis: Background Patients with mean pulmonary artery pressures (mPAP) of 21–24 mmHg have ‘borderline’ pulmonary arterial hypertension (PAH) and may represent an early, milder stage of pulmonary vasculopathy in those at high risk of PAH. 1 Case detection strategies would facilitate investigation of natural history and the value of intervention. Objectives Post-hoc analysis of systemic sclerosis (SSc) patients from the DETECT study to examine baseline characteristics of those with normal mPAP, borderline PAH (boPAP), and PAH. Methods DETECT was a multicentre cross-sectional study conducted to develop an evidence-based tool for detecting PAH in SSc patients to limit missed PAH diagnoses. Adults with SSc for >3 years, a DLCO Results Of 466 SSc patients, 187 had normal mPAP, 57 boPAP, and 87 PAH. Differences in baseline characteristics are given in the tablex. In univariable analyses (normal vs boPAP), older age (OR 1.03), peripheral oedema (OR 5.12), greater left atrium size (OR 1.12), greater right atrial area (OR 1.08), greater TR velocity (OR 2.99), higher mean PCWP (OR 1.34), and higher PVR (OR 1.01) were statistically significant and associated with boPAP. Conclusions In this post-hoc analysis, older age, peripheral oedema, echocardiographic findings, and individual RHC parameters were able to distinguish SSc patients with normal mPAP from those with boPAP. Guided by clinical suspicion, RHC remains the crucial diagnostic procedure. References Bae S et al. Ann Rheum Dis 2012;71:1335–42. Disclosure of Interest : D. Khanna Grant/research support from: Actelion, BMS, Gilead, Genentech, ISDIN, United Therapeutics, Consultant for: Actelion, BMS, Gilead, Genentech, ISDIN, United Therapeutics, Bayer, Sanofi-Aventis, Merck, Roche, Speakers bureau: Actelion, United Therapeutics, O. Distler Grant/research support from: Actelion, Pfizer, Ergonex, Sanofi-Aventis, Consultant for: Actelion, Pfizer, Boehringer-Ingelheim, Bayer, Roche, Ergonex, BMS, Sanofi-Aventis, United Biosource Corporation, Medac, Biovitrium, Novartis, Active Biotech, 4D Science, Sinoxa, Speakers bureau: Actelion, Pfizer, Ergonex, J. Coghlan Grant/research support from: Actelion, Pfizer, GSK, United Therapeutics, Consultant for: Actelion, Pfizer, GSK, United Therapeutics, Speakers bureau: Actelion, Pfizer, GSK, United Therapeutics, C. Denton Grant/research support from: Actelion Pharmaceuticals Ltd, Pfizer, GSK, Sanofi-Aventis, and Novartis, Consultant for: Actelion Pharmaceuticals Ltd, Pfizer, GSK, Sanofi-Aventis, and Novartis, Speakers bureau: Actelion Pharmaceuticals Ltd, Pfizer, GSK, Sanofi-Aventis, and Novartis, E. Grunig Grant/research support from: Actelion, Bayer, GSK, Encysive, Lilly, Pfizer, Consultant for: Actelion, Bayer, Gilead, GSK, Lilly, Milteney, Novartis, Pfizer, Rotex Medica, Speakers bureau: Actelion, Bayer, Gilead, GSK, Lilly, Milteney, Novartis, Pfizer, Rotex Medica, D. Bonderman Grant/research support from: Actelion, Consultant for: Actelion, U. Muller-Ladner Grant/research support from: Actelion, Consultant for: Actelion, Speakers bureau: Actelion, Pfizer, GSK, J. Pope Grant/research support from: Actelion, Amgen, Abbott, BMS, UCB, Janssen, Roche, Celgene, Consultant for: Actelion, Amgen, Abbott, BMS, Pfizer, UCB, Janssen, Roche, GSK, Speakers bureau: Amgen, BMS, Pfizer, M. Vonk Grant/research support from: Actelion, Pfizer, GSK, United Therapeutics, Therabel Pharma, Consultant for: Actelion, Pfizer, Speakers bureau: Actelion, Pfizer, J.-V. Torres-Martin Employee of: Actelion, M. Doelberg Shareholder of: Actelion, Employee of: Actelion, H. Chadha-Boreham Shareholder of: Actelion, Employee of: Actelion, H. Heinzl Grant/research support from: Roche Austria, Consultant for: Actelion, D. Rosenberg Shareholder of: Actelion, Employee of: Actelion, V. McLaughlin Grant/research support from: Actelion, Bayer, Novartis, United Therapeutics, Consultant for: Actelion, Bayer, Gilead, United Therapeutics, Speakers bureau: Actelion, Gilead, United Therapeutics, J. Seibold Grant/research support from: Actelion, Gilead, United Therapeutics, Consultant for: Actelion, Pfizer, Gilead, United Therapeutics, Boehringer-Ingelheim, Bayer, Sigma Tau, FibroGen, Sanofi-Aventis, Celgene, MedImmune, Genentech, InterMune
Databáze: OpenAIRE
Externí odkaz: